8-K: Mineralys Therapeutics Completes Enrollment in Launch-HTN Trial Ahead of Schedule, Topline Data Expected Mid-2025

Mineralys Therapeutics announced the completion of enrollment in its Launch-HTN trial ahead of schedule, with topline data expected in the mid first half of 2025.

Summary

• Mineralys Therapeutics has completed enrollment in the Launch-HTN trial ahead of schedule.
• The Launch-HTN trial is the second of two pivotal trials evaluating lorundrostat for uncontrolled or resistant hypertension.
• Topline data from the Launch-HTN trial is now expected in the mid first half of 2025.
• The trial is a global, randomized, double-blinded, placebo-controlled Phase 3 trial.
• Participants in the trial were on two to five background antihypertensive medications and were randomized to placebo, lorundrostat 50 mg, or lorundrostat 50 mg titrated to 100 mg.
• The primary endpoint is the change from baseline in systolic blood pressure versus placebo after six weeks of treatment.
• The company is also hosting a virtual KOL event to discuss hypertension and the lorundrostat clinical program.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the early completion of enrollment and the anticipation of topline data. However, the presence of risk factors and forward-looking statements temper the overall optimism.

Positives

• The completion of enrollment ahead of schedule suggests strong interest and efficient trial execution.
• The anticipated topline data in mid first half of 2025 is earlier than initially planned.
• Lorundrostat has demonstrated a 70% reduction in plasma aldosterone concentration in previous trials.
• The trial design models real-world treatment of uncontrolled and resistant hypertension in a primary care setting.

Negatives

• The document mentions potential risks and uncertainties that could affect the trial results and the development of lorundrostat.
• There is a dependence on third parties for manufacturing, research, and clinical testing.
• The company relies on an exclusive license with Mitsubishi Tanabe Pharma for lorundrostat.

Risks

• The company's future performance is entirely dependent on the success of lorundrostat.
• There are potential delays in the commencement, enrollment, and completion of clinical trials.
• The FDA may not approve the proposed pivotal program for lorundrostat.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat could limit its development.
• The company is subject to regulatory developments in the US and foreign countries.
• The company's reliance on its exclusive license with Mitsubishi Tanabe Pharma is a risk.

Future Outlook

The company anticipates announcing topline data for the Launch-HTN trial in the mid first half of 2025 and is continuing to develop lorundrostat for hypertension and chronic kidney disease.

Management Comments

• David Rodman, MD, Chief Medical Officer of Mineralys Therapeutics, stated that the trial is designed to model the real-world treatment of uHTN and rHTN using lorundrostat in the primary care setting.
• Management expressed appreciation for the enthusiasm and commitment of trial investigators and participants.

Industry Context

The announcement is relevant to the pharmaceutical industry, particularly companies focused on cardiovascular and renal diseases. The completion of enrollment ahead of schedule is a positive sign for the development of lorundrostat, which is targeting a significant unmet need in hypertension treatment.

Comparison to Industry Standards

• The trial design, a randomized, double-blinded, placebo-controlled Phase 3 trial, is consistent with industry standards for evaluating new pharmaceutical treatments.
• The focus on uncontrolled and resistant hypertension aligns with the need for new therapies in this area, as less than 50% of hypertension patients achieve their blood pressure goals with current medications.
• The use of an aldosterone synthase inhibitor is a novel approach, as dysregulated aldosterone levels are a key factor in driving hypertension in approximately 25% of all hypertensive patients.
• Other companies developing treatments for hypertension include Novartis with Entresto and AstraZeneca with Farxiga, however, these are not direct comparables as they are not aldosterone synthase inhibitors.

Stakeholder Impact

• Shareholders may react positively to the news of the completed enrollment and the anticipated topline data.
• Patients with uncontrolled or resistant hypertension may benefit from the development of lorundrostat.
• Physicians may be interested in the potential of lorundrostat as a new treatment option.
• Employees of Mineralys Therapeutics are likely to be impacted by the progress of the clinical trial.

Next Steps

• The company will analyze the data from the Launch-HTN trial.
• The company will announce topline data in the mid first half of 2025.
• The company will continue the development of lorundrostat for hypertension and chronic kidney disease.
• The company will host a virtual KOL event to discuss the unmet need in hypertension and the lorundrostat program.

Key Dates

Keywords

lorundrostat, hypertension, clinical trial, Launch-HTN, aldosterone synthase inhibitor, uncontrolled hypertension, resistant hypertension, Phase 3 trial, cardiovascular disease, chronic kidney disease